Suppressing effect of a novel epitopes DNA vaccine on mouse melanoma growth

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2009, Vol. 14 ›› Issue (7): 785-789.

Previous Articles Next Articles

Suppressing effect of a novel epitopes DNA vaccine on mouse melanoma growth

SHANG Ming-hong¹, LIN Sen-sen², SUN Li², ZHANG Yan-kai¹, YUAN Sheng-tao², ZHANG Lu-yong¹

¹New Drug Screening Center, China Pharmaceutical University, ²Jiangsu Service Center for Pharmacodynamics Research and Evaluation, Nanjing 210038, Jiangsu, China

Received:2009-04-06 Revised:2009-04-30 Online:2009-07-26 Published:2020-10-30

Abstract

Abstract: AIM: Construction of MAGE-1(161-169) DNA vaccine and evaluated its anti-melanoma effects in mouse.METHODS: A DNA vaccine pcDNA3.1-HSP70-MAGE-1(161-169) has been constructed and used to immunize mice 3 times at 2-weekly intervals.Two weeks after the last immunization, tumor challenge experiments were performed by using B16F10 melanoma cell.After 14 d of challenge experiments, all mice were sacrificed and tumors were weighted.The specific anti-MAGE-1 IgG antibodies and the IFN-γreleased by mouse primary splenocytes were detected by ELISA methods.RESULTS: The specific anti-MAGE-1 antibodies were detected in the serum of the mice immunized with pcDNA3.1-HSP70-MAGE-1(161-169) DNA vaccine.It showed that B16F10 melanoma growth in mice of DNA vaccine group was obviously suppressed compared with that in saline control group, with tumor inhibitory rate of 40.7%.The IFN-γ released by mouse primary splenocytes in mice of HSP70-MAGE-1(161-169) DNA vaccine group was 3.05 times of that in saline control group.CONCLUSION: pcDNA3.1-HSP70-MAGE-1(161-169) may be an effective DNA vaccine for the treatment of MAGE-1 dependent tumors.

Key words: DNA vaccine, immunogenicity, mouse melanoma

CLC Number:

R965.2

SHANG Ming-hong, LIN Sen-sen, SUN Li, ZHANG Yan-kai, YUAN Sheng-tao, ZHANG Lu-yong. Suppressing effect of a novel epitopes DNA vaccine on mouse melanoma growth[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(7): 785-789.

References

[1] Ding M, Beck RJ, Keller CJ, et al.Cloning and analysis of MAGE-1-related genes [J].Biochem Biophys Res Commun, 1994, 202(1):549-555.
[2] Amar-Costesec A, Godelaine D, Stockert E, et al.The tumor protein MAGE-1 is located in the cytosol of human melanoma cells [J].Biochem Biophys Res Commun, 1994, 204(2):710-715.
[3] Marchand M, Brasseur F, van der Bruggen P, et al.Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1 [J].Dermatology, 1993, 186(4):278-280.
[4] Ottaviani S, Zhang Y, Boon T, et al.A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells [J].Cancer Immunol Immunother, 2005, 54(12):1214-1220.
[5] Williams JA, Carnes AE, Hodgson CP.Plasmid DNA vaccine vector design:Impact on efficacy, safety and upstream production [J].Biotechnol Adv, 2009 Feb 20.
[6] Koller MF, MohajeriMH, Huber M, et al.Active immunization of mice with an Abeta-Hsp70 vaccine [J].Neurodegener Dis, 2004, 1(1):20-28.
[7] Yoshikawa T, Niwa T, Mizuguchi H, et al.Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency [J].Gene Ther, 2008, 15(19):1321-1329.
[8] 徐道华, 周晨慧, 夏永鹏, 等.宫颈癌治疗性多肽疫苗的合成及其诱导细胞毒性T 淋巴细胞效应的研究 [J].中国临床药理学与治疗学, 2007, 12(2):494-498.
[9] 欧阳可栋, 过为, 吴国君, 等.胃泌素释放肽DNA 疫苗抑制EM16 乳腺癌生长的实验研究 [J].中国临床药理学与治疗学, 2007, 12(5):512-515.
[10] You Z, Huang X, Hester J, et al.Targeting dendritic cells to enhance DNA vaccine potency [J].Cancer Res, 2001, 61(9):3704-3711.
[11] 张彦凯, 严荣, 严明, 等.新型抗β-HCG 基因疫苗的构建及其协同GM-CSF 佐剂的抗肿瘤作用 [J].中国天然药物, 2006, 4(3):234-237.
[12] Wei WZ, Jacob J, Radkevich-Brown O, et al.The “A, B and C” of Her-2 DNA vaccine development [J].Cancer Immunol Immunother, 2008, 57(11):1711-1717.

Suppressing effect of a novel epitopes DNA vaccine on mouse melanoma growth

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 7

Recommended Articles

Metrics

Comments

[1]	CHE Jinjing, LI Na. General considerations on bioanalytical methods for comparative evaluation of biosimilars immunogenicity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 721-728.
[2]	Min CHEN. immunogenicity of bispecific antibodies [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1208-1212.
[3]	HOU Liping, YAN Yuyang, LI Li, YANG Jianbo, OUYANG Dongsheng. Development of quantitative analysis methods of Rituximab and it's biosimilar in biological samples [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 98-104.
[4]	ZHANG Xiao-qing, LIU Si-bo, DOU Yun-peng, DU Yu-xuan, YUAN Hui-hui, ZHAO Wen-ming. Construction and protection effects of the dual expression DNA vaccine pCMV-DKK1/IL10 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1211-1217.
[5]	DENG Li-juan, LIN Fei, LIU Li-hua. Study on immunogenicity of recombinant glucagons-like peptide-1(7-36) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(12): 1388-1391.
[6]	OUYANG Ke-dong, GUO Wei, WU Guo-jun, ZHANG Shu-ya, LIU Jing-jing. Suppressing effect of gastrin-releasing peptide DNA vaccine on EMT6 breast cancer growth [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(5): 512-515.
[7]	YU Yong-Sheng, CHEN You-Hua. Recent advances in genetic therapy for anti-hepatitis B virus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(6): 574-576.